KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Asset Writedowns and Impairment: 2011-2014

Historic Asset Writedowns and Impairment for Sarepta Therapeutics (SRPT) over the last 1 years, with Mar 2014 value amounting to $17.0 million.

  • Sarepta Therapeutics' Asset Writedowns and Impairment changed negligibly% to $17.0 million in Q1 2014 from the same period last year, while for Mar 2014 it was $68.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $109,000 for FY2011, which is 73.28% down from last year.
  • As of Q1 2014, Sarepta Therapeutics' Asset Writedowns and Impairment stood at $17.0 million, which was down 0.00% from $17.0 million recorded in Q4 2013.
  • Over the past 5 years, Sarepta Therapeutics' Asset Writedowns and Impairment peaked at $17.0 million during Q2 2011, and registered a low of $17.0 million during Q2 2011.
  • For the 3-year period, Sarepta Therapeutics' Asset Writedowns and Impairment averaged around $17.0 million, with its median value being $17.0 million (2014).